SURROZEN INC (SRZN) Fundamental Analysis & Valuation

NASDAQ:SRZN • US86889P2083

Current stock price

28.9 USD
+0.9 (+3.21%)
At close:
28.51 USD
-0.39 (-1.35%)
After Hours:

This SRZN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SRZN Profitability Analysis

1.1 Basic Checks

  • SRZN had negative earnings in the past year.
  • In the past year SRZN has reported a negative cash flow from operations.
  • In the past 5 years SRZN always reported negative net income.
  • SRZN had a negative operating cash flow in each of the past 5 years.
SRZN Yearly Net Income VS EBIT VS OCF VS FCFSRZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -92.41%, SRZN is doing worse than 73.60% of the companies in the same industry.
Industry RankSector Rank
ROA -92.41%
ROE N/A
ROIC N/A
ROA(3y)-88.27%
ROA(5y)-71.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRZN Yearly ROA, ROE, ROICSRZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

  • SRZN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRZN Yearly Profit, Operating, Gross MarginsSRZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. SRZN Health Analysis

2.1 Basic Checks

  • SRZN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SRZN has more shares outstanding
  • Compared to 5 years ago, SRZN has less shares outstanding
  • SRZN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SRZN Yearly Shares OutstandingSRZN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SRZN Yearly Total Debt VS Total AssetsSRZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • SRZN has an Altman-Z score of -4.14. This is a bad value and indicates that SRZN is not financially healthy and even has some risk of bankruptcy.
  • SRZN has a Altman-Z score (-4.14) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.14
ROIC/WACCN/A
WACC9.37%
SRZN Yearly LT Debt VS Equity VS FCFSRZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • SRZN has a Current Ratio of 13.15. This indicates that SRZN is financially healthy and has no problem in meeting its short term obligations.
  • SRZN's Current ratio of 13.15 is amongst the best of the industry. SRZN outperforms 88.05% of its industry peers.
  • A Quick Ratio of 13.15 indicates that SRZN has no problem at all paying its short term obligations.
  • The Quick ratio of SRZN (13.15) is better than 88.05% of its industry peers.
Industry RankSector Rank
Current Ratio 13.15
Quick Ratio 13.15
SRZN Yearly Current Assets VS Current LiabilitesSRZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SRZN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 28.28% over the past year.
EPS 1Y (TTM)28.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-19.39%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.66% on average over the next years. This is quite good.
  • The Revenue is expected to decrease by -23.49% on average over the next years. This is quite bad
EPS Next Y37.58%
EPS Next 2Y30.59%
EPS Next 3Y20.44%
EPS Next 5Y10.66%
Revenue Next Year-28.12%
Revenue Next 2Y-48.8%
Revenue Next 3Y-36%
Revenue Next 5Y-23.49%

3.3 Evolution

SRZN Yearly Revenue VS EstimatesSRZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2025 2026 2027 2029 2030 2031 2032 2033 20M 40M 60M 80M 100M
SRZN Yearly EPS VS EstimatesSRZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. SRZN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SRZN. In the last year negative earnings were reported.
  • Also next year SRZN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRZN Price Earnings VS Forward Price EarningsSRZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRZN Per share dataSRZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

  • SRZN's earnings are expected to grow with 20.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.59%
EPS Next 3Y20.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SRZN Dividend Analysis

5.1 Amount

  • SRZN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SRZN Fundamentals: All Metrics, Ratios and Statistics

SURROZEN INC

NASDAQ:SRZN (3/27/2026, 8:00:00 PM)

After market: 28.51 -0.39 (-1.35%)

28.9

+0.9 (+3.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-30
Inst Owners124.42%
Inst Owner Change40.96%
Ins Owners0.58%
Ins Owner Change2.06%
Market Cap247.67M
Revenue(TTM)10.65M
Net Income(TTM)-86.91M
Analysts84.44
Price Target41.82 (44.71%)
Short Float %3.52%
Short Ratio2.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-148.45%
Min EPS beat(2)-622.12%
Max EPS beat(2)325.23%
EPS beat(4)1
Avg EPS beat(4)-292.69%
Min EPS beat(4)-622.12%
Max EPS beat(4)325.23%
EPS beat(8)4
Avg EPS beat(8)-135.54%
EPS beat(12)6
Avg EPS beat(12)-83.79%
EPS beat(16)9
Avg EPS beat(16)-59.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.38%
PT rev (3m)10.81%
EPS NQ rev (1m)-2.3%
EPS NQ rev (3m)-2.3%
EPS NY rev (1m)20.69%
EPS NY rev (3m)20.69%
Revenue NQ rev (1m)32.2%
Revenue NQ rev (3m)32.2%
Revenue NY rev (1m)4.95%
Revenue NY rev (3m)4.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 68.72
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-15.32
EYN/A
EPS(NY)-4.52
Fwd EYN/A
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0.42
BVpS-2.74
TBVpS-2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -92.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.27%
ROA(5y)-71.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.44%
Cap/Sales 2.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.15
Quick Ratio 13.15
Altman-Z -4.14
F-Score3
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)19.96%
Cap/Depr(5y)33.21%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y37.58%
EPS Next 2Y30.59%
EPS Next 3Y20.44%
EPS Next 5Y10.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-19.39%
Revenue Next Year-28.12%
Revenue Next 2Y-48.8%
Revenue Next 3Y-36%
Revenue Next 5Y-23.49%
EBIT growth 1Y-42.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-73.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.68%
OCF growth 3YN/A
OCF growth 5YN/A

SURROZEN INC / SRZN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SURROZEN INC (SRZN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SRZN.


What is the valuation status of SURROZEN INC (SRZN) stock?

ChartMill assigns a valuation rating of 1 / 10 to SURROZEN INC (SRZN). This can be considered as Overvalued.


Can you provide the profitability details for SURROZEN INC?

SURROZEN INC (SRZN) has a profitability rating of 0 / 10.


Can you provide the financial health for SRZN stock?

The financial health rating of SURROZEN INC (SRZN) is 4 / 10.